4.9200
+0.0400
+(0.82%)
At close: January 10 at 8:07:46 AM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
23,838.0010
--
18,567.9620
19,242.9690
15,342.2040
Cost of Revenue
17,470.8630
--
10,919.1830
10,587.0400
8,479.3780
Gross Profit
6,367.1380
--
7,648.7790
8,655.9290
6,862.8260
Operating Expense
9,632.1900
--
9,947.7220
8,398.5440
8,243.1790
Operating Income
-3,265.0520
--
-2,298.9430
257.3850
-1,380.3530
Net Non Operating Interest Income Expense
-526.0380
--
-195.4360
-295.5490
-385.2470
Other Income Expense
-14.5570
--
8.2460
-30.9630
733.3470
Pretax Income
-3,805.6470
--
-2,486.1330
-69.1270
-1,032.2530
Tax Provision
5.3680
--
7.6720
9.1650
-10.1360
Net Income Common Stockholders
-3,811.0150
--
-2,493.8050
-78.2920
-1,022.1170
Diluted NI Available to Com Stockholders
-3,811.0150
--
-2,493.8050
-78.2920
-1,022.1170
Basic EPS
-0.49
-0.75
-0.32
-0.01
-0.14
Diluted EPS
-0.49
-0.75
-0.32
-0.01
-0.14
Basic Average Shares
7,868.8570
7,748.0000
7,745.0000
7,592.0000
7,213.0000
Diluted Average Shares
7,868.8570
7,748.0000
7,745.0000
7,592.0000
7,213.0000
Total Operating Income as Reported
-3,265.0520
--
-2,298.9430
257.3850
-1,380.3530
Total Expenses
27,103.0530
--
20,866.9050
18,985.5840
16,722.5570
Net Income from Continuing & Discontinued Operation
-3,811.0150
--
-2,493.8050
-78.2920
-1,022.1170
Normalized Income
-3,799.5150
--
-2,501.1163
-55.6890
-1,911.6924
Interest Income
58.9120
--
153.1000
18.8100
27.4400
Interest Expense
565.6160
--
348.5360
306.5180
412.6870
Net Interest Income
-526.0380
--
-195.4360
-295.5490
-385.2470
EBIT
-3,240.0310
--
-2,137.5970
237.3910
-619.5660
EBITDA
-551.8130
--
349.9860
2,698.5310
1,727.7170
Reconciled Cost of Revenue
17,470.8630
--
10,919.1830
10,587.0400
8,479.3780
Reconciled Depreciation
2,688.2180
--
2,487.5830
2,461.1400
2,347.2830
Net Income from Continuing Operation Net Minority Interest
-3,811.0150
--
-2,493.8050
-78.2920
-1,022.1170
Total Unusual Items Excluding Goodwill
-14.5570
--
7.3340
-30.9630
898.3970
Total Unusual Items
-14.5570
--
7.3340
-30.9630
898.3970
Normalized EBITDA
-537.2560
--
342.6520
2,729.4940
829.3200
Tax Rate for Calcs
0.0002
--
0.0000
0.0003
0.0000
Tax Effect of Unusual Items
-3.0570
--
0.0227
-8.3600
8.8216
12/31/2020 - 5/18/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
RVMDW Revolution Medicines, Inc.
0.1700
-2.86%
ROVI.VI Laboratorios Farmaceuticos Rovi, S.A.
61.80
-1.12%
SPL.AX Starpharma Holdings Limited
0.1100
0.00%
CLDWW Calidi Biotherapeutics, Inc.
0.0091
+506.67%
PBM Psyence Biomedical Ltd.
1.7000
-7.61%
MGNX MacroGenics, Inc.
3.1800
-5.07%
COCP Cocrystal Pharma, Inc.
2.2100
-7.14%
RVMD Revolution Medicines, Inc.
41.78
-5.94%
AGIO Agios Pharmaceuticals, Inc.
34.42
-4.12%
OCUL Ocular Therapeutix, Inc.
8.21
-7.44%